according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Mometasone Lotion Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person

responsible for the SDS

: EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

#### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Flammable liquids, Category 2 H225: Highly flammable liquid and vapour. Eye irritation, Category 2 H319: Causes serious eye irritation.

Specific target organ toxicity - single ex-

posure, Category 3

H336: May cause drowsiness or dizziness.

Long-term (chronic) aquatic hazard, Cat-

H411: Toxic to aquatic life with long lasting effects.

egory 2

### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms





Signal word : Danger

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version 5.0	Revision Date: 06.04.2024	SDS Number: 1291627-0002	Date of last issue: 30.09.2023 Date of first issue: 15.02.2017
Hazard statements		: H225 H319 H336	Highly flammable liquid and vapour. Causes serious eye irritation.
		H411	May cause drowsiness or dizziness.  Toxic to aquatic life with long lasting effects.
Precau	tionary statements	: Prevention	:
	·	P210	Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
		P233	Keep container tightly closed.
		P273	Avoid release to the environment.
		P280	Wear protective gloves/ protective clothing/ eye protection/ face protection.
		Response:	
		P304 + P34	0 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.

#### Hazardous components which must be listed on the label:

P391

Propan-2-ol

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Collect spillage.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Vapours may form explosive mixture with air.

### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

Components

Componente			
Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Propan-2-ol	67-63-0	Flam. Liq. 2; H225	>= 30 - < 50
	200-661-7	Eye Irrit. 2; H319	
	603-117-00-0	STOT SE 3; H336	
Mometasone	83919-23-7	Repr. 1B; H360Df	>= 0.1 - < 0.25

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version	Revision Date: 06.04.2024	SDS Number:	Date of last issue: 30.09.2023
5.0		1291627-00020	Date of first issue: 15.02.2017
			STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410  M-Factor (Chronic aquatic toxicity): 100

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Causes serious eye irritation.

May cause drowsiness or dizziness.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Mometasone Lotion Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1291627-00020
 Date of first issue: 15.02.2017

### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

High volume water jet

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Do not use a solid water stream as it may scatter and spread

fire.

Flash back possible over considerable distance. Vapours may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

#### 5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Remove all sources of ignition.

Ventilate the area.

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Non-sparking tools should be used.

Soak up with inert absorbent material.

Suppress (knock down) gases/vapours/mists with a water

spray jet.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

#### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Use explosion-proof electrical, ventilating and lighting equip-

ment.

Advice on safe handling : Do not get on skin or clothing.

Avoid breathing mist or vapours.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Non-sparking tools should be used. Keep container tightly closed.

Keep away from heat, hot surfaces, sparks, open flames and

other ignition sources. No smoking.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment,

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1291627-00020
 Date of first issue: 15.02.2017

appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations. Keep away from heat and sources of ignition.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides Flammable solids Pyrophoric liquids Pyrophoric solids

Self-heating substances and mixtures

Substances and mixtures, which in contact with water, emit

flammable gases

Explosives Gases

Very acutely toxic substances and mixtures

7.3 Specific end use(s)

Specific use(s) : No data available

# **SECTION 8: Exposure controls/personal protection**

# 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
Propan-2-ol	67-63-0	OELV - 8 hrs	200 ppm	IE OEL
		(TWA)		
	Further inform	nation: Substances w	which have the capacity to pe	netrate intact
	skin when the	y come in contact w	ith it, and be absorbed into th	ie body
		OELV - 15 min	400 ppm	IE OEL
		(STEL)		
	Further information: Substances which have the capacity to penetrate intact			
	skin when they come in contact with it, and be absorbed into the body			
Propylene glycol	57-55-6	OELV - 8 hrs	10 mg/m3	IE OEL
		(TWA) (particles)		
		OELV - 8 hrs	150 ppm	IE OEL
		(TWA) (total (va-	470 mg/m3	
		pour and parti-		
		cles))		
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Mometasone Lotion Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1291627-00020	Date of first issue: 15.02.2017

Wipe limit 10 μg/100 cm<sup>2</sup> Internal

# Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Propan-2-ol	Workers	Inhalation	Long-term systemic effects	500 mg/m3
	Workers	Skin contact	Long-term systemic effects	888 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	89 mg/m3
	Consumers	Skin contact	Long-term systemic effects	319 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	26 mg/kg bw/day
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3

# Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Propan-2-ol	Fresh water	140.9 mg/l
	Marine water	140.9 mg/l
	Intermittent use/release	140.9 mg/l
	Sewage treatment plant	2251 mg/l
	Fresh water sediment	552 mg/kg dry weight (d.w.)
	Marine sediment	552 mg/kg dry weight (d.w.)
	Soil	28 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	160 mg/kg food
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry weight (d.w.)
	Marine sediment	57.2 mg/kg dry weight (d.w.)
	Soil	50 mg/kg dry weight (d.w.)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

#### 8.2 Exposure controls

#### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Use explosion-proof electrical, ventilating and lighting equipment.

### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving. Take note that the product is flam-

mable, which may impact the selection of hand protection.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Physical state : lotion

Colour : colourless, clear, to, translucent

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

Flammability (solid, gas) : Not applicable

Flammability (liquids) : Ignitable (see flash point)

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : 18.4 °C

Method: closed cup

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : 4.5

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### Mometasone Lotion Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

### **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Highly flammable liquid and vapour.

Vapours may form explosive mixture with air. Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

#### **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

### Acute toxicity

Not classified based on available information.

#### **Components:**

# Propan-2-ol:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 25 mg/l

Exposure time: 6 h Test atmosphere: vapour

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of :

administration)

LD50 (Rat): 300 mg/kg

Application Route: Subcutaneous Symptoms: Breathing difficulties

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

### Propan-2-ol:

Species : Rabbit

Result : No skin irritation

#### Mometasone:

Species : Rabbit

Result : No skin irritation

### Serious eye damage/eye irritation

Causes serious eye irritation.

#### **Components:**

#### Propan-2-ol:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

#### Mometasone:

Species : Rabbit

Result : No eye irritation

### Respiratory or skin sensitisation

### Skin sensitisation

Not classified based on available information.

### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

### Propan-2-ol:

Test Type : Buehler Test Exposure routes : Skin contact

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Mometasone:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitiser.

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Propan-2-ol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral

Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1291627-00020
 Date of first issue: 15.02.2017

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

### Propan-2-ol:

Species : Rat

Application Route : inhalation (vapour)

Exposure time : 104 weeks

Method : OECD Test Guideline 451

Result : negative

#### Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

#### Reproductive toxicity

Not classified based on available information.

#### Components:

### Propan-2-ol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

**Application Route: Ingestion** 

Result: negative

Effects on foetal develop-

: Test Type: Embryo-foetal development Species: Rat

ment

Application Route: Ingestion

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

Result: negative

Mometasone:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.015 mg/kg body weight

Symptoms: Reduced embryonic survival, Reduced foetal

weight

Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-

tal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on

sexual function and fertility, based on animal experiments.

#### STOT - single exposure

May cause drowsiness or dizziness.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1291627-00020
 Date of first issue: 15.02.2017

**Components:** 

Propan-2-ol:

Assessment : May cause drowsiness or dizziness.

Mometasone:

Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure

Not classified based on available information.

**Components:** 

Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

**Components:** 

Propan-2-ol:

Species : Rat NOAEL : 12.5 mg/l

Application Route : inhalation (vapour)

Exposure time : 104 Weeks

Mometasone:

Species : Rat

NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

NOAEL : 0.00013 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

Species : Dog

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

NOAEL : 0.0005 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

#### **Aspiration toxicity**

Not classified based on available information.

#### **Components:**

#### Mometasone:

Not applicable

#### 11.2 Information on other hazards

#### **Endocrine disrupting properties**

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

### Experience with human exposure

#### **Components:**

#### Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

**Further information** 

### **Components:**

Mometasone:

Remarks : Dermal absorption possible

### **SECTION 12: Ecological information**

#### 12.1 Toxicity

#### **Components:**

#### Propan-2-ol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 9,640 mg/l

Exposure time: 96 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### Mometasone Lotion Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1291627-00020 Date of first issue: 15.02.2017 5.0

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 10,000 mg/l

Exposure time: 24 h

Toxicity to microorganisms : EC50 (Pseudomonas putida): > 1,050 mg/l

Exposure time: 16 h

Mometasone:

Toxicity to fish LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.00014 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.34 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### Mometasone Lotion Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1291627-00020 Date of first issue: 15.02.2017 5.0

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic 100

toxicity)

### 12.2 Persistence and degradability

#### **Components:**

Propan-2-ol:

Biodegradability : Result: rapidly degradable

BOD/COD BOD: 1,19 (BOD5)

> COD: 2,23 BOD/COD: 53 %

Mometasone:

Biodegradability Result: Not readily biodegradable.

> Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

Hydrolysis: 50 %(12 d) Stability in water

Method: OECD Test Guideline 111

#### 12.3 Bioaccumulative potential

#### **Components:**

Propan-2-ol:

Partition coefficient: n-

octanol/water

: log Pow: 0.05

Mometasone:

Species: Lepomis macrochirus (Bluegill sunfish) Bioaccumulation

> Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 4.68

#### 12.4 Mobility in soil

#### **Components:**

Mometasone:

Distribution among environ- : log Koc: 4.02

mental compartments

#### 12.5 Results of PBT and vPvB assessment

#### **Product:**

Assessment This substance/mixture contains no components considered

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Mometasone Lotion Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1291627-00020
 Date of first issue: 15.02.2017

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

Empty containers retain residue and can be dangerous. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose such containers to heat, flame, sparks, or other sources of ignition. They may explode and cause injury and/or death. If not otherwise specified: Dispose of as unused product.

#### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : UN 1219
ADR : UN 1219
RID : UN 1219
IMDG : UN 1219
IATA : UN 1219

#### 14.2 UN proper shipping name

ADN : ISOPROPANOL, SOLUTION
ADR : ISOPROPANOL, SOLUTION
RID : ISOPROPANOL, SOLUTION

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

IMDG : ISOPROPANOL, SOLUTION

(Mometasone)

IATA : Isopropanol, solution

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 3
ADR : 3
RID : 3
IMDG : 3
IATA : 3

14.4 Packing group

ADN

Packing group : II
Classification Code : F1
Hazard Identification Number : 33
Labels : 3

ADR

Packing group : II
Classification Code : F1
Hazard Identification Number : 33
Labels : 3
Tunnel restriction code : (D/E)

**RID** 

Packing group : II
Classification Code : F1
Hazard Identification Number : 33
Labels : 3

**IMDG** 

Packing group : II
Labels : 3
EmS Code : F-E, S-D

IATA (Cargo)

Packing instruction (cargo : 364

aircraft)

Packing instruction (LQ) : Y341 Packing group : II

Labels : Flammable Liquids

IATA (Passenger)

Packing instruction (passen: 353

ger aircraft)

Packing instruction (LQ) : Y341
Packing group : II

Labels : Flammable Liquids

14.5 Environmental hazards

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

**ADN** 

Environmentally hazardous : yes

**ADR** 

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

#### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 75, 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

If you intend to use this product as tattoo ink, please contact your vendor.

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) No 1005/2009 on substances that de-

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation

Not applicable

Not applicable

Not applicable

Not applicable

: Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2
P5c FLAMMABLE LIQUIDS 5,000 t 50,000 t

E2 ENVIRONMENTAL 200 t 500 t

**HAZARDS** 

### Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H225
Highly flammable liquid and vapour.
H319
Causes serious eye irritation.
H336
May cause drowsiness or dizziness.

H360Df : May damage the unborn child. Suspected of damaging fertili-

ty.

H373 : May cause damage to organs through prolonged or repeated

exposure if inhaled.

H410 : Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation
Flam. Liq. : Flammable liquids
Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min : Occupational exposure limit value (15-minute reference peri-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



#### Mometasone Lotion Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1291627-00020 Date of first issue: 15.02.2017

(STEL) od)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail: SADT - Self-Accelerating Decomposition Temperature: SDS - Safety Data Sheet: SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

compile the Safety Data Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

#### Classification of the mixture:

#### Classification procedure:

Flam. Liq. 2	H225	Based on product data or assessment
Eye Irrit. 2	H319	Calculation method
STOT SE 3	H336	Calculation method
Aquatic Chronic 2	H411	Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Mometasone Lotion Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1291627-00020
 Date of first issue: 15.02.2017

considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN